Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Sees Large Drop in Short Interest

Key Points

• Basilea Pharmaceutica AG experienced a 90.5% decrease in short interest in July, dropping from 7,400 shares to just 700 shares.
• The company's stock remained stable at $67.75, with a 52-week high matching the current price and a low of $47.50.
• Basilea focuses on the development of biopharmaceutical products, including its antifungal drug Cresemba for treating invasive infections.

Basilea Pharmaceutica AG (OTCMKTS:BPMUF - ) was the target of a significant decrease in short interest during the month of July. As of July 31st, there was short interest totaling 700 shares, adecreaseof90.5% from the July 15th total of 7,400 shares. Based on an average trading volume of 100 shares, the short-interest ratio is currently 7.0 days. Currently,0.0% of the company's shares are sold short. Currently,0.0% of the company's shares are sold short. Based on an average trading volume of 100 shares, the short-interest ratio is currently 7.0 days.

Basilea Pharmaceutica Price Performance

BPMUF stock remained flat at $67.75 during trading on Thursday. The stock's 50 day moving average is $61.24 and its 200 day moving average is $54.61. Basilea Pharmaceutica has a 52 week low of $47.50 and a 52 week high of $67.75. The company has a quick ratio of 4.16, a current ratio of 4.85 and a debt-to-equity ratio of 1.18.

About Basilea Pharmaceutica

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.